share_log

Capri, Coursera, DexCom And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Benzinga ·  Oct 25 21:14

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Friday.

Shares of Capri Holdings Limited (NYSE:CPRI) fell sharply in today's pre-market trading following reports that a judge has blocked the company's pending merger with Tapestry.

Following an eight-day trial in which the U.S. Federal Trade Commission argued that a merger between Capri and Tapestry would remove competition from the U.S. handbag space, a U.S. judge has moved to block the pending merger, according to Reuters.

Capri shares tumbled 47.1% to $22.01 in pre-market trading.

Here are some big stocks recording losses in today's pre-market trading session.

  • Coursera, Inc. (NYSE:COUR) shares dipped 19.2% to $6.16 in today's pre-market trading after the company issued fourth-quarter revenue guidance below estimates and cut its FY24 revenue guidance,
  • The Bancorp, Inc. (NASDAQ:TBBK) shares declined 15.4% to $46.51 following downbeat quarterly results.
  • Joby Aviation, Inc. (NYSE:JOBY) dipped 8.1% to $5.55 in pre-market trading as the company announced the pricing of public offering of common stock.
  • Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares fell 7.8% to $2.36 in pre-market trading. Tevogen Bio recently announced its Artificial Intelligence effort, Tevogen AI, has joined Microsoft for Startups.
  • DexCom, Inc. (NASDAQ:DXCM) shares fell 6.6% to $69.89 in pre-market trading following third-quarter results.
  • Sibanye Stillwater Limited (NYSE:SBSW) declined 4.6% to $4.73 in pre-market trading after surging more than 12% on Thursday.
  • The Boston Beer Company, Inc. (NYSE:SAM) shares fell 4% to $289.80 in pre-market trading following third-quarter results.
  • Masimo Corporation (NASDAQ:MASI) shares fell 4% to $135.23 in pre-market trading. Masimo will report third quarter financial results, after the closing bell on Tuesday, Nov. 5.

Now Read This:

  • Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment